Multimodal education improves sun protective behaviors among melanoma patients: a non-randomized controlled trial

被引：0
|
作者：
Fritsche, Madelaine [1 ]
Samaan, Christen [2 ]
Wirth, Paul [3 ]
Wallace, Tierney [2 ]
Lam, Charlene [2 ]
机构：
[1] Penn State Coll Med, 700 HMC Cres Rd, Hershey, PA USA
[2] Penn State Hershey Med Ctr, 500 Univ Dr,HU14, Hershey, PA 17033 USA
[3] Buffalo Med Grp, 425 Essjay Rd,Suite 180, Williamsville, NY USA
来源：
ARCHIVES OF DERMATOLOGICAL RESEARCH | 2023年 / 315卷 / 10期
关键词：
Melanoma; Multimodal education; Infographic; Video; Sun-protective behaviors; VIDEO;
D O I：
10.1007/s00403-023-02708-0
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：2985 / 2987
页数：3
相关论文
共 39 条
  • [31] Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster Trial
    Marce, Diane
    Le Vilain-Abraham, Floriane
    Bridou, Morgiane
    Quereux, Gaelle
    Dupuy, Alain
    Lesimple, Thierry
    Le Corre, Yannick
    Wierzbicka-Hainaut, Ewa
    Legoupil, Delphine
    Celerier, Philippe
    Maillard, Herve
    Machet, Laurent
    Caille, Agnes
    CANCERS, 2022, 14 (16)
  • [32] Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies
    Han, Xiao
    Ge, Pu
    Liu, Siyu
    Yang, Dandan
    Zhang, Jinzi
    Wang, Xinpei
    Liang, Weiting
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [33] The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial)
    Holmberg, Carl-Jacob
    Zijlker, Lisanne P.
    Katsarelias, Dimitrios
    Huibers, Anne E.
    Wouters, Michel W. J. M.
    Schrage, Yvonne
    Reijers, Sophie J. M.
    van Thienen, Johannes V.
    Grunhagen, Dirk J.
    Martner, Anna
    Nilsson, Jonas A.
    van Akkooi, Alexander C. J.
    Ny, Lars
    van Houdt, Winan J.
    Bagge, Roger Olofsson
    EJSO, 2024, 50 (06):
  • [34] Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BOF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
    Saiag, Philippe
    Robert, Caroline
    Grob, Jean -Jacques
    Mortier, Laurent
    Dereure, Olivier
    Lebbe, Celeste
    Mansard, Sandrine
    Grange, Florent
    Neidhardt, Eve-Marie
    Lesimple, Thierry
    Machet, Laurent
    Bedane, Christophe
    Maillard, Herve
    Dalac-Rat, Sophie
    Szenik, Alexandra
    Nardin, Charlee
    Denden, Amine
    Dutriaux, Caroline
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 57 - 65
  • [35] Effect of online infographics for enhancing health literacy among patients with type 2 diabetes in primary care unit during the COVID-19 pandemic: a randomized controlled trial
    Sutthiworapon, Suchada
    Vichitkunakorn, Polathep
    Choomalee, Kittisakdi
    Ngamchaliew, Pitchayanont
    BMC PRIMARY CARE, 2024, 25 (01):
  • [36] Effect of online infographics for enhancing health literacy among patients with type 2 diabetes in primary care unit during the COVID-19 pandemic: a randomized controlled trial
    Suchada Sutthiworapon
    Polathep Vichitkunakorn
    Kittisakdi Choomalee
    Pitchayanont Ngamchaliew
    BMC Primary Care, 25
  • [37] A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
    Yanina Jansen
    Vibeke Kruse
    Jurgen Corthals
    Kelly Schats
    Pieter-Jan van Dam
    Teofila Seremet
    Carlo Heirman
    Lieve Brochez
    Mark Kockx
    Kris Thielemans
    Bart Neyns
    Cancer Immunology, Immunotherapy, 2020, 69 : 2589 - 2598
  • [38] A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
    Jansen, Yanina
    Kruse, Vibeke
    Corthals, Jurgen
    Schats, Kelly
    van Dam, Pieter-Jan
    Seremet, Teofila
    Heirman, Carlo
    Brochez, Lieve
    Kockx, Mark
    Thielemans, Kris
    Neyns, Bart
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) : 2589 - 2598
  • [39] Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
    Chick, Robert C.
    Faries, Mark B.
    Hale, Diane F.
    Kemp Bohan, Phillip M.
    Hickerson, Annelies T.
    Vreeland, Timothy J.
    Myers, John W., III
    Cindass, Jessica L.
    Brown, Tommy A., II
    Hyngstrom, John
    Berger, Adam C.
    Jakub, James W.
    Sussman, Jeffrey J.
    Shaheen, Montaser
    Clifton, Guy T.
    Park, Hyohyun
    Sloan, Amanda J.
    Wagner, Thomas
    Peoples, George E.
    CANCER MEDICINE, 2021, 10 (13): : 4302 - 4311
1234